NCT05519085 2026-03-11
SUCCESSOR-1
Celgene
Phase 3 Recruiting
Clinical Trials
29 trialsNCT02718833 2026-01-22
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT02343042 2025-12-22
STOMP
Karyopharm Therapeutics Inc
Phase 1/2 Recruiting
NCT03989414 2024-11-29
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Celgene
Phase 1/2 Active not recruiting
NCT03110562 2024-08-21
BOSTON
Karyopharm Therapeutics Inc
Phase 3 Completed
NCT02654990 2024-07-12
PANORAMA_3
pharmaand GmbH
Phase 2 Completed
NCT02773030 2024-06-25
A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma
Celgene
Phase 1/2 Active not recruiting
NCT01913730 2023-12-13
Maintenance Therapy With Subcutaneous Bortezomib
European Myeloma Network B.V.
Phase 2 Completed
NCT03651128 2022-12-15
KarMMa-3
Celgene
Phase 3 Active not recruiting
NCT00464178 2022-07-20
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Hackensack Meridian Health
Phase 2 Terminated
NCT00256776 2021-10-18
MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation
European Society for Blood and Marrow Transplantation
Phase 3 Terminated
NCT00773838 2021-04-01
MK-0683-095
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00708292 2020-12-17
A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.
Novartis
Phase 1/2 Completed
NCT01497093 2020-04-07
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Celgene
Phase 1 Completed
NCT01023308 2020-03-17
PANORAMA-1
Novartis
Phase 3 Completed
NCT02290431 2019-11-18
Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma
Novartis
Phase 2 Completed
NCT01470131 2018-12-19
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
AB Science
Phase 3 Terminated
NCT01672736 2018-09-13
A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma
University Health Network, Toronto
Phase 1/2 Terminated
NCT01083602 2017-12-21
MACS1271
Novartis
Phase 2 Completed
NCT01359657 2016-03-16
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Bristol-Myers Squibb
Phase 1 Completed
NCT00706953 2015-04-06
A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Withdrawn
NCT00536575 2013-02-27
Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT00335348 2013-01-09
Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse
Peter MacCallum Cancer Centre, Australia
Phase 2 Completed
NCT00752518 2011-05-17
A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients
Janssen Pharmaceutical K.K.
Phase 1/2 Completed
NCT00602511 2011-02-09
Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma
Nordic Myeloma Study Group
Phase 3 Completed
NCT00508209 2010-06-22
Bortezomib and High-dose Melphalan at Myeloma Relapse
Nordic Myeloma Study Group
Phase 2 Unknown
NCT00080405 2009-03-27
Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma
Millennium Pharmaceuticals, Inc.
Phase 1 Completed
NCT00352742 2008-10-28
A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma
Attenuon
Phase 1/2 Terminated
NCT00063791 2007-02-14
A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE
Millennium Pharmaceuticals, Inc.
No longer available